TP53 and leukemia: In addition, venetoclax has limited utility for the treatment of solid tumors, which are generally not dependent on BCL-2 for survival; however, BCL-XL can be overexpressed in many solid tumors, as well as in a subset of leukemia cells, and its expression is highly correlated with chemoresistance, independent of TP53 mutational status [79].